Journal Mobile Options
Table of Contents
Vol. 28, No. 5, 2009
Issue release date: December 2009
Dement Geriatr Cogn Disord 2009;28:476–485
(DOI:10.1159/000258100)

Patterns of Cortical Thickness according to APOE Genotype in Alzheimer’s Disease

Gutiérrez-Galve L. · Lehmann M. · Hobbs N.Z. · Clarkson M.J. · Ridgway G.R. · Crutch S. · Ourselin S. · Schott J.M. · Fox N.C. · Barnes J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Possession of one or more apolipoprotein E (APOE) ε4 alleles may influence the distribution of atrophy and clinical phenotype. We aimed to assess the influence of APOE genotype on cortical thickness and regional brain volumes in AD (Alzheimer’s disease). Methods: We included 38 patients (9 ε4 non-carriers, 23 ε4 heterozygotes, 6 ε4 homozygotes) and 23 controls. Each subject had 2 magnetic resonance imaging (MRI) scans and a neuropsychological battery. Cortical thickness and isthmus cingulate volume were measured using FreeSurfer; the volumes of the hippocampus, whole brain, and lateral ventricles were calculated using manual and semi-automated volumetry. Results: Compared with controls, cortical thickness was significantly lower: in the bilateral temporal, posterior parietal and occipital regions in non-carriers, in the medial temporal and left parietal regions in heterozygotes, and in the medial temporal lobe in homozygotes. Comparisons between AD subgroups did not show significant differences. A trend for larger brain and isthmus cingulate volumes and smaller hippocampal and ventricular volumes with increasing ε4 dose were seen. These differences were supported by neuropsychological profiles. Conclusion: These results suggest that APOE genotype may influence the topography of regional atrophy and cortical thinning in AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Wimo A, Winblad B, Guero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63–67.
  2. Godbolt AK, Cipolotti L, Watt H, Fox NC, Janssen JC, Rossor MN: The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol 2004;61:1743–1748.
  3. Scheltens P, Fox N, Barkhof F, De Carli C: Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13–21.
  4. Okuizumi K, Onodera O, Tanaka H, Kobayashi H, Tsuji S, Takahashi H, Oyanagi K, Seki K, Tanaka M, Naruse S, Miyatake T, Mizusawa H, Kanazawa I: APOE-epsilon-4 and early-onset Alzheimers. Nat Genet 1994;7:10–11.
  5. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when–not whether–one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321–322.
  6. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM: Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326–335.
  7. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Partanen K, Ryynanen M, Vainio P, Hartikainen P, Riekkinen PJ: Volumes of hippocampus, amygdala and frontal-lobe in Alzheimer patients with different apolipoprotein-E genotypes. Neuroscience 1995;67:65–72.
  8. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer’s disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000;68:93–96.
  9. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E: Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology 2001;57:1461–1466.
  10. Pievani M, Rasser PE, Galluzzi S, Benussi L, Ghidoni R, Sabattoli F, Bonetti M, Binetti G, Thompson PM, Frisoni GB: Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer’s disease in vivo. Neuroimage 2009;45:1090–1098.
  11. Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, Boxer AL, Karydas A, Possin KL, Gorno-Tempini ML: Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer’s disease and frontotemporal dementia. Proc Natl Acad Sci USA 2009;106:2018–2022.
  12. Filippini N, Rao A, Wetten S, Gibson RA, Borrie M, Guzman D, Kertesz A, Loy-English I, Williams J, Nichols T, Whitcher B, Matthews PM: Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer’s disease. Neuroimage 2009;44:724–728.
  13. Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, Rossor MN, Fox NC: Apolipoprotein E genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006;63:155–156.
  14. van der Flier WM, Schoonenboom SN, Pijnenburg YA, Fox NC, Scheltens P: The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006;67:526–527.
  15. Barnes J, Foster J, Boyes RG, Pepple T, Moore EK, Schott JM, Frost C, Scahill RI, Fox NC: A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neuroimage 2008;40:1655–1671.
  16. Barnes J, Boyes RG, Lewis EB, Schott JM, Frost C, Scahill RI, Fox NC: Automatic calculation of hippocampal atrophy rates using a hippocampal template and the boundary shift integral. Neurobiol Aging 2007;28:1657–1663.
  17. Barnes J, Scahill RI, Frost C, Schott JM, Rossor MN, Fox NC: Increased hippocampal atrophy rates in AD over 6 months using serial MR imaging. Neurobiol Aging 2008;29:1199–1203.
  18. Schott JM, Frost C, Whitwell JL, MacManus DG, Boyes RG, Rossor MN, Fox NC: Combining short interval MRI in Alzheimer’s disease: Implications for therapeutic trials. J Neurol 2006;253:1147–1153.
  19. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC: Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 2005;65:119–124.
  20. Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC: Neuropsychological correlates of whole brain atrophy in Alzheimer’s disease. Neuropsychologia 2008;46:1732–1737.
  21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  22. Dale AM, Fischl B, Sereno MI: Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999;9:179–194.
  23. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  24. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  25. Fischl B, Sereno MI, Dale AM: Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9:195–207.
  26. Fischl B, Dale AM: Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:11050–11055.
  27. Chung MK, Robbins SM, Dalton KM, Davidson RJ, Alexander AL, Evans AC: Cortical thickness analysis in autism with heat kernel smoothing. Neuroimage 2005;25:1256–1265.
  28. Freeborough PA, Fox NC, Kitney RI: Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15–25.
  29. Sled JG, Zijdenbos AP, Evans AC: A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87–97.
  30. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J: A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89–101.
  31. Fox NC, Warrington EK, Stevens JM, Rossor MN: Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann NY Acad Sci 1996;777:226–232.
  32. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC: A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003;60:989–994.
  33. Whitwell JL, Crum WR, Watt HC, Fox NC: Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001;22:1483–1489.
  34. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM: Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–355.
  35. Jones BF, Barnes J, Uylings HB, Fox NC, Frost C, Witter MP, Scheltens P: Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. Cereb Cortex 2006;16:1701–1708.
  36. Genovese CR, Lazar NA, Nichols T: Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870–878.
  37. Free SL, Bergin PS, Fish DR, Cook MJ, Shorvon SD, Stevens JM: Methods for normalization of hippocampal volumes measured with MR. AJNR Am J Neuroradiol 1995;16:637–643.
  38. Galton CJ, Patterson K, Xuereb JH, Hodges JR: Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123:484–498.
  39. Braak H, Braak E: Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271–278.
  40. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC: Focal decline of cortical thickness in Alzheimer’s disease identified by computational neuroanatomy. Cereb Cortex 2005;15:995–1001.
  41. Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ: Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s disease. Brain 2006;129:2885–2893.
  42. Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW: Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain 2007;130:1159–1166.
  43. Im K, Lee JM, Seo SW, Yoon U, Kim ST, Kim YH, Kim SI, Na DL: Variations in cortical thickness with dementia severity in Alzheimer’s disease. Neurosci Lett 2008;436:227–231.
  44. Basso M, Yang J, Warren L, MacAvoy MG, Varma P, Bronen RA, van Dyck CH: Volumetry of amygdala and hippocampus and memory performance in Alzheimer’s disease. Psychiatry Res 2006;146:251–261.
  45. Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, Eustache F: In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. Neuroimage 2001;14:298–309.
  46. Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, Laakso MP: Detection of grey matter loss in mild Alzheimer’s disease with voxel based morphometry. J Neurol Neurosurg Psychiatry 2002;73:657–664.
  47. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, Barkhof F: Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004;23:708–716.
  48. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericakvance MA: Protective effect of apolipoprotein-E type-2 allele for late-onset Alzheimer disease. Nat Genet 1994;7:180–184.
  49. Boccardi M, Sabattoli F, Testa C, Beltramello A, Soininen H, Frisoni GB: APOE and modulation of Alzheimer’s and frontotemporal dementia. Neurosci Lett 2004;356:167–170.
  50. Pennanen C, Testa C, Boccardi M, Laakso MP, Hallikainen M, Helkala EL, Hanninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H: The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. Dement Geriatr Cogn Disord 2006;22:60–66.
  51. Thomann PA, Roth AS, Dos Santos V, Toro P, Essig M, Schroder J: Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:300–305.
  52. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, Ryynanen M, Kuikka J, Hartikainen P, Riekinnen PJ: SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996;60:644–649.
  53. Geroldi C, Pihlajamaki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832.
  54. Jack CR Jr, Petersen RC, Xu YC, O’Brien PC, Waring SC, Tangalos EG, Smith GE, Ivnik RJ, Thibodeau SN, Kokmen E: Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol 1998;43:303–310.
  55. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, Morris CM, O’Brien JT: Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961–965.
  56. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, Pritchard A, Lendon CL, Richardson AM, Varma A, Neary D, Mann DMA: Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex 2007;43:835–845.
  57. Jenkins R, Fox NC, Rossor AM, Harvey RJ, Rossor MN: Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. Arch Neurol 2000;57:220–224.
  58. Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50